The Filing Desk

BioCryst Pharmaceuticals vs Lakefront Biotherapeutics NV

BioCryst Pharmaceuticals BCRX · Lakefront Biotherapeutics NV LKFT · Biotechnology

BioCryst Pharmaceuticals reported revenue of $875 million in fiscal 2025, and Lakefront Biotherapeutics NV €1.1 billion in fiscal 2025, in different currencies. BioCryst Pharmaceuticals' revenue grew 94.1% in its latest year, and Lakefront Biotherapeutics NV's grew 303.5%. BioCryst Pharmaceuticals had an operating margin of 39.0%, against 26.5% at Lakefront Biotherapeutics NV. Free cash flow was $345 million at BioCryst Pharmaceuticals and −€271 million at Lakefront Biotherapeutics NV.

Side by side

BioCryst PharmaceuticalsLakefront Biotherapeutics NV
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$875M€1.1B
Revenue growth94.1%303.5%
Revenue growth a year, last 5 years117.9%18.4%
Gross margin97.8%97.3%
Operating margin39.0%26.5%
Net margin30.2%28.9%
Free cash flow$345M−€271M
Free cash flow margin39.4%−24.4%
Return on capital——
Net debt to EBITDA−0.8x—
Dividends and buybacks$0M€0M
Change in diluted share count5.8%0.0%
Last close$7.32$33.39
P/E at the last close——
Insider trades, last 12 monthssold $4.1 million—
Piotroski F-score7 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
BioCryst PharmaceuticalsLakefront Biotherapeutics NV
Operating margin
Percent of revenue
BioCryst PharmaceuticalsLakefront Biotherapeutics NV
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
BioCryst PharmaceuticalsLakefront Biotherapeutics NV

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioCryst Pharmaceuticals and Lakefront Biotherapeutics NV pages.